{"nctId":"NCT00887653","briefTitle":"Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy","startDateStruct":{"date":"2009-05"},"conditions":["HIV","Hyperlipidemia","Hypertriglyceridemia","HIV Infections"],"count":20,"armGroups":[{"label":"Raltegravir","type":"EXPERIMENTAL","interventionNames":["Drug: raltegravir"]}],"interventions":[{"name":"raltegravir","otherNames":["Isentress"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age \\>18\n* Fasting LDL\\>130 mg/dL\n* Fasting triglycerides \\>250 mg/dL\n* Plasma viral load below 50 copies/mL on current regimen for 6 months prior to study entry.\n* No prior history of any NRTI resistance.\n\nExclusion Criteria:\n\n* History of NRTI resistance mutations\n* Need for medications that have drug interactions with raltegravir: dilantin, phenobarbitol and rifampin\n* Unstable clinical condition, such as unstable cardiac disease, or cancer requiring ongoing chemotherapy or radiation therapy, or other medical condition which, in the opinion of the investigator, would preclude a subject from safely undergoing study procedures.\n* Breast-feeding or pregnancy.\n* Use of immunosuppressive medications within 60 days prior to study entry.\n* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline Triglycerides","description":"Assess changes from baseline triglycerides at 3 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Plasma Viral Load Below the Limit of Detection","description":"Assess proportion of patients with PVL below limit of detection at end of study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline Triglycerides","description":"Assess changes from baseline triglycerides at 6 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":20},"commonTop":[]}}}